JP Morgan Chase
HAE icon

JP Morgan Chase’s Haemonetics HAE Stock Holding History

JP Morgan Chase’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,900
Closed -$4.26M – 6174
2020
Q4 		$4.26M Buy
+35,900
New +$3.86M ﹤0.01% 2950
2020
Q3 		– Sell
-34,500
Closed -$3.09M – 5586
2020
Q2 		$3.09M Buy
+34,500
New +$3.48M ﹤0.01% 2814

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase's HAE Position: Q1 2026 in Review

JP Morgan Chase increased its Haemonetics (HAE) stake by 28% in Q1 2026, buying an estimated $4.71M and bringing the position to 328,909 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2161.

JP Morgan Chase first reported a position in HAE in Q2 2013 and has held it in 48 quarters since. The position peaked at $81.3M in Q3 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • JP Morgan Chase held 328,909 shares of Haemonetics worth $18.1M as of Q1 2026.
  • JP Morgan Chase bought 72,356 Haemonetics shares in Q1 2026, an estimated $4.71M.
  • Haemonetics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2161 holding.
  • JP Morgan Chase first reported a position in Haemonetics in Q2 2013 and has held it in 48 quarters since.
  • JP Morgan Chase's Haemonetics position peaked at $81.3M in Q3 2018.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.